Candida tropicalis fungaemia: Incidence, risk factors and mortality in a general hospital

Clinical Microbiology and Infection

Volumn 17, Issue 10, 2011, Pages 1538-1545

  Munoz P ^a   Giannella, M ^a   Fanciulli, C ^a   Guinea, J ^a   Valerio, M ^a   Rojas, L ^a   Rodriguez Creixems M ^a   Bouza, E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Candida tropicalis; Candidaemia; Fungaemia; Invasive candidiasis; Non albicans Candida species

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; PREDNISONE; PYRROLE; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CASE CONTROL STUDY; CATHETER REMOVAL; CLINICAL FEATURE; FEMALE; GENERAL HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; RISK FACTOR; SACCHAROMYCES CEREVISIAE; SEPTIC SHOCK; URINARY TRACT INFECTION;

CANDIDA; CANDIDA TROPICALIS;

EID: 80053062911     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03338.x     Document Type: Article

References (30)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
2. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-320.
3. Rodriguez-Creixems M, Alcala L, Munoz P, Cercenado E, Vicente T, Bouza E. Bloodstream infections: evolution and trends in the microbiology workload, incidence, and etiology, 1985-2006. Medicine (Baltimore) 2008; 87: 234-249.
4. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Clin Microbiol Infect 2006; 12: 170-177.
5. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
6. Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-1618.
7. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-1850.
8. Bedini A, Venturelli C, Mussini C et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2006; 12: 75-80.
9. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21-27.
10. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
11. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005; 26: 548-552.
12. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
13. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681-1685.
14. Myoken Y, Kyo T, Fujihara M, Sugata T, Mikami Y. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies. Haematologica 2004; 89: 378-380.
15. Leung AY, Chim CS, Ho PL et al. Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect 2002; 50: 316-319.
16. Kontoyiannis DP, Vaziri I, Hanna HA et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001; 33: 1676-1681.
17. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
18. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
19. Rodriguez-Tudela JL, Martinez-Suarez JV. Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. J Antimicrob Chemother 1995; 35: 739-749.
20. Rodriguez-Tudela JL, Martinez-Suarez JV, Dronda F, Laguna F, Chaves F, Valencia E. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antimicrob Chemother 1995; 35: 793-804.
21. Nucci M, Colombo AL. Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 2007; 58: 77-82.
22. Chai YA, Wang Y, Khoo AL et al. Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. Med Mycol 2007; 45: 435-439.
23. Chakrabarti A, Chatterjee SS, Rao KL et al. Recent experience with fungaemia: change in species distribution and azole resistance. Scand J Infect Dis 2009; 41: 275-284.
24. Aquino VR, Lunardi LW, Goldani LZ, Barth AL. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis 2005; 9: 411-418.
25. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-2823.
26. Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11-16.
27. Chen KW, Chen YC, Lin YH, Chou HH, Li SY. The molecular epidemiology of serial Candida tropicalis isolates from ICU patients as revealed by multilocus sequence typing and pulsed-field gel electrophoresis. Infect Genet Evol 2009; 9: 912-920.
28. Li SY, Yang YL, Lin YH et al. Two closely related fluconazole-resistant Candida tropicalis clones circulating in Taiwan from 1999 to 2006. Microb Drug Resist 2009; 15: 205-210.
29. Roilides E, Farmaki E, Evdoridou J et al. Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen. J Clin Microbiol 2003; 41: 735-741.
30. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-2972.